Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.

Nguyen E, Coleman CI, Kohn CG, Weeda ER. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. Int J Cardiol. 2018 Dec 15; 273:34-38.

View in: PubMed

subject areas

Cardiovascular Agents
Cohort Studies
Cost-Benefit Analysis
Diabetes Mellitus, Type 2
Female
Humans
Male
Markov Chains
Prospective Studies
Quality of Life

authors with profiles

Elaine Nguyen

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support